In Brief: Warner-Lambert
This article was originally published in The Tan Sheet
Executive Summary
Warner-Lambert: Reports completion of its purchase of Glaxo Wellcome's U.S. and European interest in the Warner Wellcome joint venture on July 1; the purchase originally was announced Dec. 19, 1995 ("The Tan Sheet" Jan. 1, p. 5). Purchase agreements totaling $150 mil. for Glaxo Wellcome interests in Canada, Mexico, Australia and New Zealand should be complete by third quarter 1996. The entire transaction will carry a $1.05 bil. pricetag and will bring "a variety of well-known OTC products, such as Sudafed, Actifed, Neosporin, and Nix, directly under the Warner-Lambert name," the company notes...
|
Warner-Lambert: Reports completion of its purchase of Glaxo Wellcome's U.S. and European interest in the Warner Wellcome joint venture on July 1; the purchase originally was announced Dec. 19, 1995 ("The Tan Sheet" Jan. 1, p. 5). Purchase agreements totaling $150 mil. for Glaxo Wellcome interests in Canada, Mexico, Australia and New Zealand should be complete by third quarter 1996. The entire transaction will carry a $1.05 bil. pricetag and will bring "a variety of well-known OTC products, such as Sudafed, Actifed, Neosporin, and Nix, directly under the Warner-Lambert name," the company notes.... |